Tehran University of Medical Sciences Immunology and Genetics Journal 2645-4831 7 3 2024 09 22 117 136 EN Homa Seyedmirzaei Children’s Medical Center Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran; Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran Parnian Shobeiri Children’s Medical Center Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran Mehdi Mohammadi Department of Biological Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada Mohammad Zarei John B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA 2025 02 16 2025 02 16 t   The ongoing COVID-19 pandemic inflicted a considerable burden on health systems and individuals worldwide. Thus, scientists intended to propose beneficial treatments and vaccines to fight against this virus. However, vaccination remained the only effective way to reduce death and hospitalization due to COVID-19 infection. To date, about five proposed COVID-19 vaccines have been approved as WHO emergency use listings (EUL). Yet, their safety profile needs the following actions to be revealed: (1) more follow-up registry systems and (2) global clinical trials in various countries in a period that they are experiencing a peak. By searching keywords 'COVID-19' and 'vaccination' in PubMed and Scopus databases, we aimed to summarize the current evidence in the literature regarding the safety profile (i.e., local and systemic adverse events) of ten COVID-19 vaccines: (1) Pfizer/BioNTech, (2) Moderna, (3) Sputnik V, (4) Bharat, (5) CanSino, (6) Sinovac, (7) AstraZeneca, (8) Johnson & Johnson, (9) Novavax, and (10) Sinopharm. Moreover, we demonstrated the data on the safety of heterologous schedules of these vaccines alongside further considerations in people with comorbidities and particular circumstances. Most of the COVID-19 vaccine adverse effects possess a mild-to-moderate, self-limiting nature. However, special circumstances such as severe hyper-sensitivity necessitate the use of an alternate COVID-19 vaccine. Vaccination is the only way to exit the global pandemic, and its benefits outweigh its adverse effects. Meanwhile, people should be aware of the signs of the probable rare, severe reactions to the vaccine. https://igj.tums.ac.ir/index.php/igj/article/view/179 https://igj.tums.ac.ir/index.php/igj/article/download/179/147